Phelinun
melphalan
Table of contents
Overview
Phelinun is a cancer medicine for treating patients with:
- cancers of the bone marrow (which produces blood cells) – multiple myeloma, acute lymphoblastic leukaemia and acute myeloid leukaemia;
- Hodgkin and non-Hodgkin lymphomas, which are cancers that affect white blood cells called lymphocytes;
- Childhood neuroblastoma, a cancer of nerve cells in different parts of the body;
- ovarian cancer;
- mammary adenocarcinoma, a type of breast cancer.
It is used either on its own or in combination with other cancer medicines, or radiotherapy or both.
Phelinun can also be used for stem cell transplantation in adults and children with blood cancers and some other blood disorders in children. It is given with other cytotoxic (cell-killing) medicines for conditioning treatment (to clear cells in the bone marrow) before the patient receives healthy stem cells from a donor to replace the diseased cells.
Phelinun contains the active substance melphalan.
Phelinun is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, but Phelinun is intended for an additional use (conditioning treatment). The reference medicine for Phelinun is Alkeran 50 mg/10 ml, which is marketed in France.
-
List item
Phelinun : EPAR - Medicine overview (PDF/152.96 KB)
First published: 25/11/2020 -
-
List item
Phelinun : EPAR - Risk-assessment-report summary (PDF/60.18 KB)
First published: 25/11/2020
Authorisation details
Product details | |
---|---|
Name |
Phelinun
|
Agency product number |
EMEA/H/C/005173
|
Active substance |
melphalan hydrochloride
|
International non-proprietary name (INN) or common name |
melphalan
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
L01AA03
|
Publication details | |
---|---|
Marketing-authorisation holder |
ADIENNE S.r.l. S.U.
|
Revision |
1
|
Date of issue of marketing authorisation valid throughout the European Union |
16/11/2020
|
Contact address |
Via Galileo Galilei, 19 |
Product information
06/10/2021 Phelinun - EMEA/H/C/005173 - IAIN/0001
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:
- multiple myeloma,
- malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),
- acute lymphoblastic and myeloblastic leukemia,
- childhood neuroblastoma,
- ovarian cancer,
- mammary adenocarcinoma.
Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.
Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:
- Myeloablative conditioning (MAC) treatment in case of malignant haematological diseases
- RIC treatment in case of non-malignant haematological diseases.